Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
about
Infracentimetric HER-2 positive breast tumours-review of the literatureRecent advances in the field of anti-cancer immunotherapyCardiac toxicity in cancer survivorsEvaluation and management of patients with heart disease and cancer: cardio-oncologyNoninvasive imaging of cardiovascular injury related to the treatment of cancerEfficacy and learning curve of a hand-held echocardiography device in an oncology outpatient clinic: Expanding the use of echoscopic heart examination beyond cardiologyIntersection of cardiology and oncology clinical practices.Immunological Approaches in the Treatment of Metastasized Breast CancerClinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals.Genome-based risk prediction for early stage breast cancer.Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.Early detection and prediction of cardiotoxicity in chemotherapy-treated patientsDoes diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.Heart failure and chemotherapeutic agents.Breast cancer therapy-associated cardiovascular disease.Update on cardiotoxicity of anti-cancer treatments.Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy.Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.Echocardiographic evaluation of cardiac function after cancer chemotherapy.Lack of uniformity in cardiac assessment during trastuzumab therapy.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.The British Society of Echocardiography - a legacy of leadership.Detection of subclinical trastuzumab-induced cardiotoxicity in patients with breast cancer.Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium.Chemotherapy-induced Cardiotoxicity.Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
P2860
Q26774597-79F2C887-11E0-46AD-8E79-2BADD9A67F6EQ26775602-1A6DD1E0-0F81-4434-90BD-E3779D789435Q26851957-1A417CD9-F8CE-47F7-A5FA-EACB8D6AE706Q26998273-4DDE5982-CA67-474B-8CBA-63B738DD2ACBQ27024715-16C521A5-F197-4414-BB89-91750E12CF21Q30406985-A83F5C7E-FD92-43C5-988F-3AAABB3980DAQ30428702-E7F52391-7C83-468B-B24C-2A4C9FD3356BQ34140043-1030E4B2-E3BB-447C-8B91-1B37C5AA360DQ34266960-C055B66A-9E37-4626-8B2A-C390C941B1ADQ34359289-7F451B00-FEDE-46DD-B054-53EF06C8024FQ34694972-BF30165D-A8D4-4200-9CD7-CEB832ED9654Q34779675-44A4D068-4ACF-4E2C-B4E8-0B55911FF465Q35687574-5E6C0387-3C61-44AF-9D97-BF871D5F516BQ35878469-95937884-2CDF-405A-923E-D3488BEA7965Q35889261-8B5EC50F-C5D2-410A-BB6A-1D047D5B0101Q35997676-C1D9EFAB-7D53-4AD6-BBD9-6D73E14C458EQ36207305-EB6AC9FD-99CD-4A20-916B-405842C1AEBBQ36988282-6D787C2D-05D6-4A58-BE2C-2A50B56B3B4CQ37116520-FB012F86-167A-48CC-A5CC-868BC982EBE2Q37240194-D6032F79-E526-4FB2-8B3D-8424EAB61295Q37547962-D8698C96-C9B3-4777-BFA8-9AA73B7ADD11Q38416816-46C96FA6-8D09-49FA-AD7A-1F59A1CF97F9Q38559133-CD836780-490A-4D44-98C7-FD11A11F5F39Q38645182-0B6FD668-5342-41E4-96F6-F63227BC9D10Q38686222-18A6204A-0CFD-4ABB-9E79-7AF9BD198031Q38931763-192622CF-B754-4A8D-9AD3-C37E12B91DF2Q39263764-E9ECD94B-7FA2-42FB-B40B-E3781E8EB5AFQ39429845-794AC017-AFEA-4408-975A-598AB7BBE46BQ39746124-1C09C45C-3742-43DA-B946-C33644B3101FQ41288150-000A5B96-4CC0-4B74-9C9B-7D7EA5055A4EQ42265816-A0EAA314-2817-4B31-9133-19B7CD4462CEQ42333822-D172818A-1C3B-4E6D-8612-E5577190CBE0Q48344109-5628201F-9A40-4D54-A6B2-E77037D00198Q49909927-8A368CA6-8724-48F1-B634-F573507A2449Q50687140-AFE539F4-8A43-4FD5-A013-C4A98337CF0BQ50875570-2CC99B55-0FC1-4B88-A37E-E9E1063F6250Q51224671-3B555D80-F99C-45CE-B8C8-B1FAC1985C41Q51368192-51C661CE-98D9-4C9A-BADA-AA71C325AFA6Q51737126-BD3B6B07-FBEC-47E7-941A-0923B90DB32DQ54368881-C7FF9613-B8F8-4DA9-850D-DC79D0E45022
P2860
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@en
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@nl
type
label
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@en
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@nl
prefLabel
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@en
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@nl
P2093
P1433
P1476
Minimizing cardiotoxicity whil ...... ew and expert recommendations.
@en
P2093
Antonia Márquez
Bijoy Khandheria
Emilio Alba
Francisco J Esteva
José Angel García-Sáenz
José Zamorano
Leopoldo Pérez-Isla
Miguel Martín
Partho Sengupta
P356
10.1634/THEONCOLOGIST.2008-0137
P577
2009-01-15T00:00:00Z